21 CFR Part 211 Subpart B governs the organizational framework of a finished pharmaceutical manufacturer. It defines Quality Unit authority, personnel qualification standards, hygiene controls, and consultant oversight obligations. When these controls break down, FDA treats the issue as systemic risk.

From 2017 through 2025, FDA repeatedly cited manufacturers under:

21 CFR 211.22 Responsibilities of the Quality Control Unit
21 CFR 211.25 Personnel Qualifications
21 CFR 211.28 Personnel Responsibilities
21 CFR 211.34 Consultants

The PharmaBenchmark™ Subpart B Intelligence Report consolidates enforcement history across those regulations and structures it into regulation level benchmarking intelligence.

This is not a compliance summary. It is enforcement mapped to the regulation itself.

Inspectors evaluate authority before they evaluate documentation. If the Quality Unit lacks independence, technical depth, or documented control over product disposition, inspection scope expands immediately.

21 CFR 211.22 – Quality Unit Authority

FDA citations under 211.22 consistently reflect failures in one or more of the following areas:

Inadequate review of batch production records.
Failure to investigate discrepancies thoroughly.
Lack of Quality Unit independence from production pressure.
Release of product without complete review.

When FDA documents 211.22 findings, it signals governance exposure, not isolated SOP gaps.

21 CFR 211.25 – Personnel Qualifications

Enforcement trends show recurring findings tied to incomplete training records, insufficient CGMP qualification, and personnel performing critical tasks without demonstrated competency. Training systems that appear sufficient on paper often fail under inspection when cross examined against deviation history and investigation quality.

21 CFR 211.28 – Personnel Responsibilities

This regulation governs hygiene, apparel, and contamination control discipline. In sterile environments, compounding operations, and high risk manufacturing settings, breakdowns here elevate contamination risk and increase scrutiny across the facility.

21 CFR 211.34 – Consultants

FDA expects documented qualification and evaluation of external consultants. Organizations cannot outsource regulatory responsibility. When consultant oversight is weak, FDA often questions the effectiveness of the overall quality system.

Most compliance teams search FDA databases by company name. That approach obscures regulation specific trends.

The Subpart B Intelligence Report organizes enforcement data by CFR section first. It provides:

Complete citation frequency by regulation from 2017 through 2025.
Company level citation listings tied directly to specific Subpart B sections.
Inspection date correlation to identify enforcement clustering periods.
Structured data architecture for regulatory benchmarking and executive reporting.

This allows organizations to evaluate their Quality Unit governance structure against documented FDA behavior.

Regulatory Affairs leaders use Subpart B citation density to anticipate inspection focus during surveillance and pre approval inspections.

Quality Directors compare internal deviation and CAPA data against industry enforcement patterns to validate system effectiveness.

Supplier Quality teams review citation history before qualifying or requalifying contract manufacturers.

Executive leadership uses regulation specific enforcement trends to justify investment in Quality Unit authority and personnel infrastructure.

This transforms raw enforcement data into operational decision making intelligence.

The Subpart B dataset spans inspections conducted between 2017 and 2025 and includes domestic manufacturers, international firms, contract manufacturing organizations, and pharmacies operating under CGMP.

All data is extracted from official FDA enforcement documentation and structured for regulation level analysis under the PharmaBenchmark methodology.

Traceability is preserved. Enforcement references are mapped. The structure is defensible during audits and internal governance reviews.

Most organizations believe their Subpart B controls are compliant because SOPs exist. FDA evaluates execution, independence, and effectiveness.

ComplyFDA offers a structured Subpart B Baseline Assessment focused specifically on:

Quality Unit authority and independence.
Personnel qualification and CGMP competency controls.
Training documentation robustness.
Consultant qualification and oversight governance.

Within ten days, organizations receive an objective maturity score, regulation specific gap identification, prioritized remediation planning, and an executive level summary suitable for board visibility.

If your Subpart B structure has not been benchmarked against real FDA enforcement data from the last eight years, risk exposure remains unquantified.